Series D brings in $43mm for Avedro

Ophthalmic device and drug developer Avedro Inc. has raised $43mm through its Series D venture round led by Abingworth. Third Point also made a significant investment, and was joined by existing shareholders Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Venture Partners, Borealis Ventures, and Echelon Ventures. Abingworth and Third Point will gain representation on Avedro’s board. The company will use the proceeds for R&D activities involving corneal crosslinking (for cataract and refractive surgery), to gain US approval for future products, and for global commercialization.